Immunotherapy has emerged as important armamentarium in fight against TRIPLE NEGATIVE breast cancer whereas target drug like TRASTUZUMAB is vital for TRIPLE POSITIVE HER 3+ ... Oct 22
The advent of targeted therapies like antibody-drug conjugates represents a significant step forward in the battle against cancer, and the potential for further breakthroughs ... Oct 09
While the actual reduction in drug prices will depend on how manufacturers and distributors implement the GST cut, the potential savings could bring much-needed ... Sep 17
In the US, gastric cancer is most frequently diagnosed in the advanced stage, with only approximately 5% of patients surviving beyond five years.... Jan 18
New option extends dosing from two to four weeks, reducing medical visits and improving patient convenience ... Jan 15
Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs ... Dec 23
Amgen today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan® (rituximab)... Dec 18
The approval for MARGENZA was based on data from SOPHIA, a randomized Phase 3 clinical trial... Dec 17
The impact of the disease is significant, with breast cancer responsible for more than 137,000 deaths per year.... Dec 14
Enhertu continued to demonstrate impressive efficacy and durable responses in patients with HER2-positive metastatic breast cancer following two or more prior HER2-based regimens.... Dec 10
Tuznue is a mAb biosimilar to Roche’s Herceptin (trastuzumab)... Nov 13
Only HER2-directed medicine to demonstrate significant improvement in overall survival compared to chemotherapy... Oct 28
Lupin announced today the launch of Lapatinib Tablets, 250 mg, after Lupin’s alliance partner Natco Pharma Ltd received final approval for its ANDA from ... Sep 30
Lupin launches generic version of Novartis's Tykerb Tablets... Sep 30
Antibody-drug conjugate for treating different type of Cancers, starts second phase trial... Aug 25
Option would extend dosing to four weeks in non-small cell lung and bladder cancer reducing medical visits by half ... Aug 20
FDA ODD status for PBP1510 the new molecule for treating pancreatic cancer... Jun 30
Biocon Biologics receives EU GMP certification for multiple biosimilars manufacturing facilities in Bengaluru ... May 27
ONTRUZANT is Samsung Bioepis’ first oncology biosimilar available in the United States ... Apr 16
Robust growth in US markets helps Cipla to boost Q3 performance... Feb 06
Biocon witnessed a strong revenue growth of 14% to Rs 1,784 Crore in Q3FY20... Jan 25
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH),... Jan 20
True North to invest 536.24 crores in Biocon for 2.44% minority stake... Jan 07
Samsung Bioepis’ BRENZYS™ (etanercept) becomes available in Brazil through Brazil’s public health system, Sistema Único de Saúde (SUS) Established seven years ago, Samsung ... Sep 11
-Advertisements-
.jpeg)
Friday, November 22, 2024
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)